🇺🇸 FDA

Intelligence · Patents

Expiring patents (≤24 months)

Patent cliff watchlist — pharmaceutical patents approaching loss of exclusivity.

Patents
1,230

Quick answer

1,230 pharmaceutical patents in our index expire within the next 24 months. Use year facets below for annual patent-cliff planning linked to company and drug profiles.

  1. US 7354580

    Method of administering and using VEGF inhibitors for the treatment of human cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7354761

    Methods and composition for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs

    The Regents of the University of California · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7354904

    Bacteriocin inducer peptides

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7354582

    Use of VEGF antagonists for the treatment of malignant gliomas

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7354894

    Preventing airway mucus production by administration of EGF-R antagonists

    The Regents of the University of California · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7354900

    Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides

    The Board of Regents of the University of Oklahoma · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7355046

    Biphenyl derivatives

    Theravance, Inc. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7358247

    Mycophenolate mofetil impurity

    TEVA Gyógyszergyár Zártkörüen Müködö Részvénytárasaság · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7358229

    Deuterated cyclosporin analogs and their use as immunomodulating agents

    Isotechnika, Inc. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7358087

    Compositions and methods for enhancing immune responses mediated by antigen-presenting cells

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7357945

    Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7358085

    Anti-angiogenic methods and compositions

    Sangamo Biosciences, Inc. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7358226

    Ultrasonic concentration of drug delivery capsules

    The Regents of the University of California · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7358086

    Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

    The Regents of the University of California · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7358360

    Risedronate sodium having a very low content of iron

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7358273

    Inhibitors of caspases

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7358390

    Polymorphic forms of nateglinide

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7358260

    Quinuclidine derivatives and medicinal compositions containing the same

    Laboratories Almirall, S.A. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7358258

    Prodrugs of an ERK protein kinase inhibitor

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7358222

    Preventing airway mucus production by administration of EGF-R antagonists

    The Regents of the University of California · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7358377

    Schweinfurthin analogues

    The United States of America · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7358364

    Substituted carboxylic acids

    The Institute for Pharmaceutical Discovery, LLC · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7358259

    HCV inhibitors and methods of using them

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7358248

    Substituted amino carboxylic acids

    The Institute for Pharmaceutical Discovery, LLC · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7358244

    Azabicycloalkane compounds

    Theravance, Inc. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7361332

    Treating tumors using implants comprising combinations of allogeneic cells

    The Regents of the University of California · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7361665

    Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7361350

    Use of an IL-1 antagonist for treating arthritis

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7361355

    Mutant forms of cholera holotoxin as an adjuvant

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7361476

    Methionyl tRNA synthetase polynucleotides

    Replidyne, Inc. · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7361504

    Culturing Anaplasma

    Regents of the University of Minnesota · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7361664

    Vitamin D receptor antagonists and related compositions and methods of use

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7361356

    Self-assembling recombinant papillomavirus capsid proteins

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7361646

    Methods for treating gastroesophageal reflux disease

    Corcept Therapeutics Incorporated · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7361671

    Substituted heteroarylalkanoic acids

    The Institute for Pharmaceutical Discovery, LLC · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7361752

    RNAi modulation of MLL-AF4 and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7361680

    Indole compounds useful for the treatment of cancer

    The Regents of the University of California · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7361756

    Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7364719

    Vasoregulating compounds and methods of their use

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7365096

    Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)

    The Board of Regents of the University of Texas System · Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7365047

    Use of pentagastrin to inhibit gastric acid secretion or as a diuretic

    The Regents of the University of California · Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7365050

    Methods for modulating a drug-related effect or behavior

    The Regents of the University of California · Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7365072

    Inhibitors of p38

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7365092

    Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7365165

    IL-1 antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7365171

    Chemokine-like factors (CKLFs) with chemotactic and hematopoietic stimulating activities

    Beijing Medical University United Biological Engineering Company · Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7365175

    Wit 3.0, a novel gene to control soft tissue wound healing

    The Regents of the University of California · Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7364726

    Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine

    The Regents of the University of California · Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is a patent cliff?

A patent cliff is when key pharmaceutical patents expire, opening markets to generics or biosimilars. This hub lists USPTO patents with approaching expiration dates.

Are expiration dates estimates?

Expiration dates derive from USPTO PatentsView grant dates and term estimates. Confirm with Orange Book, patent counsel, and USPTO records before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.